Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Pharmacokinetics of Danoprevir in single dose
(100mg QD on day 1, day 4 and day 14) and Ritonavir-boosted Danoprevir (100mg QD on day 4 and
day 14) in single and multiple doses (100mg BID on day 5 -day 13) in healthy volunteers.